Safety of cefepime: a new extended-spectrum parenteral cephalosporin (Q44261719)

1 December 2017

0 references

Safety of cefepime: a new extended-spectrum parenteral cephalosporin (English)

1 reference

1 December 2017

H C Neu

1

1 reference

PubMed ID

8678100

1 December 2017

language of work or name

English

0 references

publication date

1 June 1996

1 reference

American Journal of Medicine

1 December 2017

1 reference

1 December 2017

100

1 reference

1 December 2017

68S-75S

1 reference

1 December 2017

6A

1 reference

Third generation cephalosporins: safety profiles after 10 years of clinical use.

1 December 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900110-6

Advances in cephalosporin therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900110-6

The use of cefepime (BMY 28142) to treat respiratory infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900110-6

A randomized trial of cefepime (BMY-28142) and ceftazidime for the treatment of pneumonia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900110-6

Open trial of cefepime (BMY 28142) for infections in hospitalized patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900110-6

Cefepime versus cefotaxime in the treatment of lower respiratory tract infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900110-6

A non-comparative study of the efficacy and tolerance of cefepime in combination with amikacin in the treatment of severe infections in patients in intensive care

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900110-6

A comparative study of cefepime and ceftazidime in the treatment of community-acquired lower respiratory tract infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900110-6

Cefepime compared with ceftazidime as initial therapy for serious bacterial infections and sepsis syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900110-6

Randomized comparison of cefepime and ceftazidime for treatment of hospitalized patients with gram-negative bacteremia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900110-6

Cefepime monotherapy for the empirical treatment of fever in granulocytopenic cancer patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900110-6

Randomized comparative study of cefepime and cefotaxime in the treatment of acute obstetric and gynaecological infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900110-6

Prospective randomized comparison of cefepime and cefotaxime for treatment of bacterial meningitis in infants and children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900110-6

Cefepime as treatment for osteomyelitis and other severe bacterial infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900110-6

Low-dosage cefepime as treatment for serious bacterial infections.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900110-6

International comparative study of cefepime and ceftazidime in the treatment of serious bacterial infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900110-6

A non-comparative, multicentre study of cefepime in the treatment of serious bacterial infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900110-6

A new therapeutic option for the treatment of pneumonia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900110-6

Clinical applications of a new parenteral antibiotic in the treatment of severe bacterial infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900110-6

Treatment of urinary tract infections: selecting an appropriate broad-spectrum antibiotic for nosocomial infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900110-6

Safety, tolerance, and pharmacokinetic evaluation of cefepime after administration of single intravenous doses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900110-6

Inhibition of granulopoiesis in vivo and in vitro by beta-lactam antibiotics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900110-6

Side effects of cephalosporins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900110-6

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0002-9343(96)00110-6

1 reference

1 December 2017

1 reference

PubMed ID

8678100